Imatinib and everolimus in patients with progressing advanced chordoma: A phase 2 clinical study

ConclusionsImatinib plus everolimus showed a limited activity in progressing advanced chordoma. Interestingly, the amount of tumor cells activated for mammalian target of rapamycin effectors correlated with the response. Toxicity was not negligible.

Source: Cancer - November 13, 2018 Category: Cancer & Oncology Authors: Silvia Stacchiotti, Carlo Morosi, Salvatore Lo Vullo, Alessandra Casale, Elena Palassini, Anna Maria Frezza, Gabriella Dinoi, Antonella Messina, Alessandro Gronchi, Adalberto Cavalleri, Elisabetta Venturelli, Daniele Morelli, Silvana Pilotti, Tags: Original Article Source Type: research